REGN vs. V

Last updated Jun 4, 2026

REGN (Regeneron Pharmaceuticals, Inc.) and V (Visa Inc.) are both stocks. REGN operates in Biotechnology (Healthcare), while V operates in Credit Services (Financial Services). Over the past 10 years, REGN returned 4.53%/yr vs 15.41%/yr for V. At a 0.31 correlation, their price movements are largely independent.

Performance

REGN vs. V - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Regeneron Pharmaceuticals, Inc. (REGN) and Visa Inc. (V). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, REGN achieves a -19.60% return, which is significantly lower than V's -10.55% return. Over the past 10 years, REGN has underperformed V with an annualized return of 4.53%, while V has yielded a comparatively higher 15.41% annualized return.

REGN

• 1D: 2.66%
• 1M: -12.60%
• YTD: -19.60%
• 6M: -14.24%
• 1Y: 27.57%
• 3Y*: -5.52%
• 5Y*: 4.04%
• 10Y*: 4.53%

V

• 1D: -1.55%
• 1M: -4.22%
• YTD: -10.55%
• 6M: -4.83%
• 1Y: -13.94%
• 3Y*: 11.79%
• 5Y*: 7.10%
• 10Y*: 15.41%

*Multi-year figures are annualized to reflect compound growth (CAGR)

REGN vs. V - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
REGN Regeneron Pharmaceuticals, Inc.	-19.60%	8.96%	-18.90%	21.73%	14.25%	30.72%	28.66%	0.53%	-0.65%	2.42%
V Visa Inc.	-10.55%	11.76%	22.32%	26.31%	-3.40%	-0.31%	17.12%	43.33%	16.49%	47.18%

Correlation

The correlation between REGN and V is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.13
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (5Y) Calculated over the trailing 5-year period	0.26
Correlation (10Y) Calculated over the trailing 10-year period	0.27
Correlation (All Time) Calculated using the full available price history since Mar 20, 2008	0.31

The correlation between REGN and V shifts across timeframes, from 0.13 (1 year) to 0.31 (all time), reflecting how their relationship changes across market environments.

Fundamentals

EPS REGN : $41.05 V : $15.24
PE Ratio REGN : 15.08 V : 20.50
PS Ratio REGN : 4.47 V : 10.59
Total Revenue (TTM) REGN : $14.92B V : $43.03B
Gross Profit (TTM) REGN : $12.61B V : $16.94B
EBITDA (TTM) REGN : $5.74B V : $27.63B

Return for Risk

REGN vs. V — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

REGN

REGN Risk / Return Rank: 64
REGN Sharpe Ratio Rank: 67
REGN Sortino Ratio Rank: 62
REGN Omega Ratio Rank: 60
REGN Calmar Ratio Rank: 62
REGN Martin Ratio Rank: 70

V

V Risk / Return Rank: 14
V Sharpe Ratio Rank: 14
V Sortino Ratio Rank: 14
V Omega Ratio Rank: 14
V Calmar Ratio Rank: 15
V Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

REGN vs. V - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Visa Inc. (V). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	REGN	V	Difference
Sharpe ratio Return per unit of total volatility	0.84	-0.63	+1.48
Sortino ratio Return per unit of downside risk	1.38	-0.79	+2.18
Omega ratio Gain probability vs. loss probability	1.17	0.90	+0.27
Calmar ratio Return relative to maximum drawdown	1.07	-0.69	+1.76
Martin ratio Return relative to average drawdown	3.78	-1.28	+5.06
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

REGN vs. V - Sharpe Ratio Comparison

The current REGN Sharpe Ratio is 0.84, which is higher than the V Sharpe Ratio of -0.63. The chart below compares the historical Sharpe Ratios of REGN and V, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	REGN	V	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.84	-0.63	+1.48
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.13	0.31	-0.18
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.14	0.63	-0.49
Sharpe Ratio (All Time) Calculated using the full available price history	0.16	0.68	-0.52

Drawdowns

REGN vs. V - Drawdown Comparison

The maximum REGN drawdown since its inception was -91.81%, which is greater than V's maximum drawdown of -51.90%. Use the drawdown chart below to compare losses from any high point for REGN and V.

Drawdown Indicators

	REGN	V	Difference
Max Drawdown Largest peak-to-trough decline	-91.81%	-51.90%	-39.91%
Max Drawdown (1Y) Largest decline over 1 year	-25.85%	-20.38%	-5.47%
Max Drawdown (3Y) Largest decline over 3 years	-59.69%	-20.38%	-39.31%
Max Drawdown (5Y) Largest decline over 5 years	-59.69%	-28.60%	-31.09%
Max Drawdown (10Y) Largest decline over 10 years	-59.69%	-36.36%	-23.33%
Current Drawdown Current decline from peak	-48.07%	-15.66%	-32.41%
Average Drawdown Average peak-to-trough decline	-42.38%	-8.26%	-34.12%
Ulcer Index Depth and duration of drawdowns from previous peaks	7.31%	10.94%	-3.63%

Volatility

REGN vs. V - Volatility Comparison

Regeneron Pharmaceuticals, Inc. (REGN) has a higher volatility of 12.35% compared to Visa Inc. (V) at 5.20%. This indicates that REGN's price experiences larger fluctuations and is considered to be riskier than V based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	REGN	V	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.35%	5.20%	+7.15%
Volatility (6M) Calculated over the trailing 6-month period	22.35%	17.26%	+5.09%
Volatility (1Y) Calculated over the trailing 1-year period	32.82%	22.11%	+10.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	30.77%	22.77%	+8.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	32.16%	24.45%	+7.71%

Dividends

REGN vs. V - Dividend Comparison

REGN's dividend yield for the trailing twelve months is around 0.59%, less than V's 0.83% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
REGN Regeneron Pharmaceuticals, Inc.	0.59%	0.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
V Visa Inc.	0.83%	0.70%	0.68%	0.72%	0.76%	0.62%	0.56%	0.56%	0.67%	0.61%	0.75%	0.64%

Financials

REGN vs. V - Profitability Comparison

The chart below illustrates the profitability comparison between Regeneron Pharmaceuticals, Inc. and Visa Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

REGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.

V - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Visa Inc. reported a gross profit of -8.90B and revenue of 11.23B. Therefore, the gross margin over that period was -79.3%.

REGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.

V - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Visa Inc. reported an operating income of 7.23B and revenue of 11.23B, resulting in an operating margin of 64.4%.

REGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.

V - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Visa Inc. reported a net income of 6.02B and revenue of 11.23B, resulting in a net margin of 53.6%.

Frequently Asked Questions

Can I hold both REGN and V in my portfolio?

REGN and V have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, REGN or V?

REGN has higher volatility (12.35%) compared to V (5.20%). In terms of maximum drawdown, REGN dropped -91.81% vs V's -51.90%.

Which has better risk-adjusted returns?

REGN currently has the higher Sharpe Ratio (0.84 vs -0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.